Third-generation CAR T-cell therapy shows promising efficacy and safety in heavily pretreated CLL patients, with a 67% complete response rate. The new CAR T-cell generation aims to mitigate exhaustion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback